An overview on anti-tubulin agents for the treatment of lymphoma patients
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference193 articles.
1. Phase I study of the anti-CD22 antibody-drug conjugate Pinatuzumab Vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma;Advani;Clinical Cancer Research,2017
2. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas;Aghajanian;Journal of Clinical Oncology,2007
3. A phase I study to assess the safety and pharmacokinetics of single-agent Lorvotuzumab Mertansine (IMGN901) in patients with relapsed and/or refractory CD-56-positive multiple myeloma;Ailawadhi;Clinical Lymphoma, Myeloma & Leukemia,2019
4. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin’s lymphoma. [comparative study];Al-Katib;Clinical Cancer Research,2009
5. Recent developments in the chemical biology of epothilones;Altmann;Current Pharmaceutical Design,2005
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A novel pyrrolidine-2,5-dione derivative induced G2/M phase arrest and apoptosis of hepatocellular carcinoma HepG2 cells through inhibiting tubulin polymerization;Arabian Journal of Chemistry;2024-02
2. Therapeutic role of 2-stearoxyphenethyl phosphocholine targeting microtubule dynamics and Wnt/β-catenin/EMT signaling in human colorectal cancer cells;Life Sciences;2023-12
3. Tumor selective self-assembled nanomicelles of carbohydrate-epothilone B conjugate for targeted chemotherapy;European Journal of Medicinal Chemistry;2023-11
4. Design, synthesis, docking studies and biological screening of 2-pyrimidinyl-2, 3-dihydro-1 H -naphtho [1, 2- e ][1, 3] oxazines as potent tubulin polymerization inhibitors;Journal of Biomolecular Structure and Dynamics;2023-10-09
5. Antibody–drug conjugates: Recent advances in payloads;Acta Pharmaceutica Sinica B;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3